Shenyang Xingqi Pharmaceutical (300573.SZ): Phase IV clinical research report achieved after the listing of Cyclosporin Eye Drops (II).

Shenyang Xingqi Pharmaceutical (300573.SZ) announced that its product Cyclosporine Eye Drops () has recently obtained the Phase IV clinical research report on the safety and effectiveness of treating dry eye. Approved indications: This product can promote tear secretion in patients with dry eye syndrome, and is suitable for patients with reduced tear production caused by eye inflammation related to corneal dryness. This study is a multicenter, prospective clinical trial. A total of 1999 subjects underwent a 24-week medication observation to evaluate the safety and effectiveness of Cyclosporine Eye Drops () for dry eye patients. The results showed that Cyclosporine Eye Drops () has good overall safety and tolerability, and can effectively improve dry eye symptoms and signs. The company's 0.05% Cyclosporine Eye Drops () was approved for marketing in June 2020 and included in the National Medical Insurance Catalog on December 3, 2021. The purpose of this clinical trial is to further evaluate the safety and effectiveness of 0.05% Cyclosporine Eye Drops () in Chinese dry eye patients. The Phase IV clinical research report will not have a significant impact on the company's recent performance.